Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide



Status:Recruiting
Conditions:Depression, Depression, Major Depression Disorder (MDD), Psychiatric
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:12 - 17
Updated:3/7/2019
Start Date:October 5, 2017
End Date:February 7, 2022
Contact:Study Contact
Email:JNJ.CT@sylogent.com
Phone:844-434-4210

Use our guide to learn which trials are right for you!

A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide

The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses
of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive
placebo (oral midazolam) in rapidly reducing the symptoms of major depressive disorder (MDD)
including suicidal ideation in participants 12 to less than 18 years of age who are assessed
to be at imminent risk for suicide.

This study will enroll participants with major depressive disorder (MDD) presenting with
suicidal ideation who are assessed to be at imminent risk for suicide. The study will be
conducted in 4 phases: a screening evaluation performed within 48 hours prior to Day 1
intranasal dose; a 25-day double-blind treatment phase (Days 1-25); an 8‑week initial
post-treatment phase (Days 25-81); and a subsequent phase to complete a full 6‑month
post-treatment follow-up (Days 81-200). Efficacy, safety, pharmacokinetic, biomarker, and
pharmacogenomic evaluations will be performed in the study at defined schedule. The duration
of the participant's participation will be approximately 29 weeks. If you or a loved one are
having thoughts of suicide, please seek immediate medical help. Go to the emergency room or
call the National Suicide Prevention Lifeline at 1-800-273-8255.

Inclusion Criteria:

- Participants must meet diagnostic and statistical manual of mental disorders (5th
edition) {DSM-5} diagnostic criteria for major depressive disorder (MDD), without
psychotic features, based upon clinical assessment and confirmed by the mini
international neuropsychiatric interview for children and adolescents (MINI KID)

- Participant must have a children's depression rating scale-revised (CDRS-R) total
score of equal or more than (>=) 58 predose on Day 1

- As part of standard of care treatment, participant must agree to be hospitalized
voluntarily for a recommended period of 5 days after randomization (may be shorter or
longer if clinically warranted in the investigator's opinion)

- As part of the newly initiated or optimized standard of care treatment, participant
must agree to take one of the prescribed non-investigational antidepressant
medications (fluoxetine, escitalopram, sertraline) at least during the double-blind
treatment phase (Day 25)

- As part of standard of care treatment, participant must agree to participate in a
specific psychological intervention (individual cognitive behavioral therapy [CBT],
interpersonal therapy, family therapy or psychodynamic psychotherapy) at least through
the initial 8-week post-treatment follow-up period (Day 81)

Exclusion Criteria:

- Participants has a current DSM-5 diagnosis of bipolar (or related disorders),
intellectual disability, autism spectrum disorder, conduct disorder, anorexia nervosa,
oppositional defiant disorder, or obsessive compulsive disorder

- Participants currently meets DSM-5 criteria for borderline personality disorder.
Participants not meeting full DSM-5 criteria for borderline personality disorder but
exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should
also be excluded

- Participant has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with
psychosis

- Participant meets the DSM-5 severity criteria for moderate or severe substance or
alcohol use disorder (except for nicotine or caffeine) within the 6 months before
screening. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid
diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related
use disorder is exclusionary

- Participant has a history of seizure disorder
We found this trial at
22
sites
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
811 Juniper St NE
Atlanta, Georgia 30308
(404) 881-5800
Atlanta Center for Medical Research Welcome to the Atlanta Center for Medical Research, a leader...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21285
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
1800 Orleans Street
Baltimore, Maryland 21224
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Brussels, 1070
?
mi
from
Brussels,
Click here to add this to my saved trials
Buffalo, New York 14222
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45220
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44106
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Hartford, Connecticut 06106
?
mi
from
Hartford, CT
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
1276 Gilbreath Drive
Johnson City, Tennessee 37614
?
mi
from
Johnson City, TN
Click here to add this to my saved trials
Lake Charles, Louisiana 70601
?
mi
from
Lake Charles, LA
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Springfield, Illinois 62702
?
mi
from
Springfield, IL
Click here to add this to my saved trials